Work

A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults

Year: 2020

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Clinical Pharmacology in Drug Development

DOI: 10.1002/cpdd.883

Authors: Antonios O. Aliprantis, Dennis Wolford, Luzelena Caro, Brian M. Maas, Hua Ma, Diana L. Montgomery, Laura M. Sterling, Allen Hunt, Kara S. Cox, Kalpit A. Vora, Brad A. Roadcap, Radha A. Railkar, Andrew W. Lee, S. Aubrey Stoch, Eseng Lai

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Celerion (United States)

Language: English

Topic: Respiratory viral infections research

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097935535

FWCI: 5.97

Cites: 27

Cited by: 69

Related to: 10